FAQ's

Where can I get a copy of the Financial Report and Accounts?
The Company aims to publish its half yearly Interim Results in August and Annual Report in March.

Cyprotex Fiscal year is 1st January to 31st December.

Cyprotex reports its accounts under IFRS (International Financial Reporting Standards).

All of Cyprotex's Annual and Interim Reports can be found online in the Annual and Interim Reports section of the web Investor Relations site. Should you wish to obtain a hard copy of any Financial Report, please contact John Dootson the Chief Financial Officer of Cyprotex PLC at 15 Beech Lane, Macclesfield, Cheshire, SK10 2DR.

What do I do if I lose my Share Certificate?
Though most Share Certificates are handled electronically now, if any shareholder requires a replacement share certificate, this can be obtained from Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

What happens if a Shareholder dies?
The Beneficiaries of the will should advise Capita Registrars Limited and send a copy of the Death Certificate.

Whom do I inform if I move house or change my name?
Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

How can I find out what my present Shareholding is?
Contact Capita Registrars Limited, Northern House, Woodsome Park, Fenay Bridge, Huddersfield, HD8 0LA.

Can I receive corporate documents in electronic form?
Yes, they will be made available either via the Company web site or via direct Contact with John Dootson the Chief Financial Officer.

What is ADME Testing?
ADME stands for Absorption, Distribution, Metabolism and Excretion. The objective of ADME testing is to measure what happens to a compound in the human physiology.

What products does Cyprotex sell?
Cyprotex has expertise in (1) the delivery of automated In vitro ADME assays with high throughput capability (2) the delivery of later stage data for potential drugs in the preclinical development phase (3) leading edge in silico QSAR and PBPK modelling capability with capacity to handle libaries of compounds based on molecular structure and other basic physical characteristics.

What are Cyprotex's USP's?

• The combination of experimental data generation and in silico prediction differentiates Cyprotex in the marketplace and provides an important competitive advantage and opportunity for customers to increase productivity.
• Cyprotex have invested heavily in automation both in terms of our laboratory and IT systems. This has enabled us to provide an unrivalled service in terms of quality, speed, capacity and cost.
• We have developed our own proprietary software, Cloe^® PK, which uses the in vitro data to predict human pharmacokinetics. 
• Only the very best scientists have been selected for managing our customer projects. From the feedback we receive, we know that the support we provide exceeds the expectations of our customers.

How does confidentiality work with clients?
Cyprotex fully understands the importance of IP to its customers and potential customers and generally signs a Confidentiality / Non Disclosure Agreement with clients; Cyprotex has its own suite of suitable Agreements.